HNSCC

This study tests a combination of three treatments—immunotherapy (tislelizumab), targeted therapy (afatinib), and a modified herpes virus (lysogenic HSV)—given before surgery for head and neck squamous cell carcinoma. The goal is to see if this approach safely shrinks tumors and …

This study tests a combination of an immunotherapy drug (pembrolizumab) and a type of internal radiation (cesium-131 brachytherapy) given during surgery for head and neck cancer that has come back. The goal is to see if this approach is safe and helps prevent the cancer from retu…

This phase 2 trial tests whether adding ramucirumab to pembrolizumab (Keytruda) works better than pembrolizumab alone for people with PD-L1 positive head and neck cancer that has come back or spread. About 37 participants will receive either the combination or the single drug. Th…

This early-phase trial tests a new approach to treat advanced solid tumors by giving patients a large dose of their own immune cells that are specially selected to attack cancer. The cells are taken from the tumor, multiplied in the lab, and then infused back. Some patients also …

This phase 2 trial tests whether adding the immunotherapy drug tirellizumab plus chemotherapy before standard surgery can improve outcomes for people with early oral squamous cell carcinoma. Sixty participants will be randomly assigned to either the drug combo plus surgery or sur…

This study tests a program called Potlako+ that combines community education, support for healthcare providers, and patient navigation to help people with cancer symptoms get diagnosed and treated faster. About 874 participants in Botswana will be split into two groups: one recei…